Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diaphragm muscle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    72 result(s) found for: Diaphragm muscle. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2018-000748-24 Sponsor Protocol Number: -- Start Date*: 2018-08-09
    Sponsor Name:VUmc
    Full Title: Partial neuromuscular blockade to facilitate lung and diaphragm protective mechanical ventilation in ICU patients. A randomized controlled pilot study.
    Medical condition: Some patients develop high respiratory drive during partially supported mechanical ventilation which is associated with lung and diaphragm injury and worse clinical outcome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002078-30 Sponsor Protocol Number: REDNES06052013 Start Date*: 2013-08-08
    Sponsor Name:Onze-Lieve-Vrouw Ziekenhuis
    Full Title: Acceleromyography and diaphragm electromyographic activity during neostigmine or sugammadex enhanced recovery from moderate residual neuromuscular blockade after rocuronium 0.6 mg kg-1: a double bl...
    Medical condition: We will compare usual care (neostigmine) with sugammadex for reversal of a moderate rocuronium-induced neuromuscular blockade and assess the effect on diaphragmatic EMG activity of sugammadex versu...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000735-26 Sponsor Protocol Number: AGN/HO/SPA/001-191622 Start Date*: 2007-06-18
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicentre, Double-Blind, Prospective, Randomised, European and Canadian Study to Evaluate Patient Outcomes and Costs of Managing Adults with Spasticity and Associated Focal Spasticity.
    Medical condition: Spasticity and Associated Focal Spasticity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001762-42 Sponsor Protocol Number: 4658-402 Start Date*: 2020-04-03
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular ...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) SE (Prematurely Ended) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011216-38 Sponsor Protocol Number: 1.02.7001 Start Date*: 2009-09-01
    Sponsor Name:Medtronic International Trading Sarl
    Full Title: A randomized, controlled, open-label, parallel-group, multicenter study to compare the effect of Intrathecal Baclofen Therapy (ITB Therapy) versus Best Medical Treatment (BMT) on severe spasticity ...
    Medical condition: Severe spasticity in post-stroke patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) BE (Completed) DE (Completed) IT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001926-25 Sponsor Protocol Number: B300201316844 Start Date*: 2013-09-23
    Sponsor Name:Universitair Ziekenhuis Antwerpen
    Full Title: Sugammadex and the diaphragm: recovery of diaphragmatic function and neuromuscular blockade
    Medical condition: Residual neuromuscular blockade and diphragm fatigue
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005222-19 Sponsor Protocol Number: BREATH Start Date*: 2016-07-14
    Sponsor Name:Leiden University Medical Center
    Full Title: Effect of neuromuscular blockade and reversal by sugammadex versus neostigmine on breathing when hypoxic or hypercapnic in volunteers
    Medical condition: Postoperative ventilatory control
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10038680 Respiratory depression postoper LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002069-52 Sponsor Protocol Number: 4045-301 Start Date*: 2017-01-23
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
    Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) SE (Completed) DE (Completed) FR (Ongoing) ES (Trial now transitioned) CZ (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) DK (Trial now transitioned) GR (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001356-22 Sponsor Protocol Number: CLR_09_21 Start Date*: 2016-07-13
    Sponsor Name:Sun Pharma Advanced Research Company Ltd.
    Full Title: A PLACEBO-CONTROLLED RANDOMIZED WITHDRAWAL EVALUATION OF THE EFFICACY AND SAFETY OF BACLOFEN ER CAPSULES (GRS) IN SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS
    Medical condition: Spasticity due to multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-000898-83 Sponsor Protocol Number: ADN016 Start Date*: 2021-11-10
    Sponsor Name:ADIENNE SA
    Full Title: A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the efficacy and safety of begelomab in combination with standard steroid and/or immunosuppressant th...
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002660-26 Sponsor Protocol Number: ONO-2506POE014 Start Date*: 2007-01-08
    Sponsor Name:ONO Pharmaceutical Co.,Ltd
    Full Title: A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED...
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) FR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000137-52 Sponsor Protocol Number: IFN-K-005-DM Start Date*: 2016-07-26
    Sponsor Name:Neovacs SA
    Full Title: A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects with Dermatomyositis.
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004018-15 Sponsor Protocol Number: V710-003 Start Date*: 2008-01-17
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult P...
    Medical condition: Staphylococcus aureus bacteremia Staphylococcus aureus mediastinitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    14.0 10021881 - Infections and infestations 10066413 Staphylococcus aureus mediastinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) AT (Completed) FR (Prematurely Ended) IE (Prematurely Ended) DK (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001886-33 Sponsor Protocol Number: MK-8616-076-00 Start Date*: 2012-10-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Randomized, Controlled, Parallel Group, Double Blind Trial to Compare the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures Using a 2x2 Fact...
    Medical condition: Patients undergoing elective in-patient laparoscopic cholecystectomy procedures under general anesthesia with neuromuscular relaxation and active reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FI (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002816-22 Sponsor Protocol Number: CTL-002-002 Start Date*: 2023-03-09
    Sponsor Name:Catalym GmbH
    Full Title: A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
    Medical condition: Muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006311-21 Sponsor Protocol Number: CBAF312A2202 Start Date*: 2009-07-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis
    Medical condition: Polymyositis and dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036102 Polymyositis LLT
    9.1 10012503 Dermatomyositis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-004987-23 Sponsor Protocol Number: CY4026 Start Date*: 2013-02-08
    Sponsor Name:Cytokinetics Inc
    Full Title: A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)
    Medical condition: Amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004567-21 Sponsor Protocol Number: 3119001 Start Date*: 2015-06-05
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension
    Medical condition: Amyotrophic lateral sclerosis (ALS). A rapidly progressive neurological disease characterized by degeneration of upper and lower motor neurons with subsequent muscle atrophy and weakness and loss ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000401-36 Sponsor Protocol Number: DSC/14/2357/48 Start Date*: 2017-03-07
    Sponsor Name:ITALFARMACO S.p.A.
    Full Title: Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002938-73 Sponsor Protocol Number: ARGX-113-1602 Start Date*: 2016-10-31
    Sponsor Name:Argenx BVBA
    Full Title: A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness
    Medical condition: Myasthenia Gravis who have Generalized Muscle Weakness
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 09:00:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA